Neuphoria Therapeutics Inc. (NEUP) income statement
NEUPNasdaqPharmaceutical PreparationsFiscal year ends June 30
Số liệu tài chính tới Q4 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-K on Sep 18, 2026Score 5/30
$2.27−0.21 (-8.47%)
Close on Nov 17, 2026Market cap $68.24KP/E –Yield –
Neuphoria Therapeutics Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY2026
- Gross margin
- –
- Operating margin
- -1401.1%
- Net margin
- -1145.7%
- Return on equity, FY2026
- -61.7%
Financial strength
- Current ratio
- 27.85
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 2625.7%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.00
- Dividend yield
- –
See a number that looks wrong?